Establishment Labs (NASDAQ:ESTA) Given New $50.00 Price Target at Citigroup

Establishment Labs (NASDAQ:ESTA) had its price target upped by Citigroup from $45.00 to $50.00 in a research report sent to investors on Tuesday morning, Benzinga reports. The firm currently has a neutral rating on the stock.

A number of other research analysts have also commented on the stock. JPMorgan Chase & Co. lowered their price objective on shares of Establishment Labs from $61.00 to $50.00 and set an overweight rating on the stock in a research note on Wednesday, August 7th. Mizuho boosted their price target on shares of Establishment Labs from $65.00 to $70.00 and gave the company a buy rating in a report on Thursday, June 6th. Finally, Stephens reaffirmed an overweight rating and issued a $68.00 price target on shares of Establishment Labs in a research report on Wednesday, August 7th. One equities research analyst has rated the stock with a hold rating and four have issued a buy rating to the company. Based on data from MarketBeat.com, Establishment Labs presently has an average rating of Moderate Buy and an average price target of $57.60.

Establishment Labs Stock Performance

Shares of ESTA stock opened at $40.56 on Tuesday. The stock has a market capitalization of $1.12 billion, a price-to-earnings ratio of -12.92 and a beta of 1.20. Establishment Labs has a one year low of $16.96 and a one year high of $60.12. The company’s 50-day simple moving average is $43.02 and its 200-day simple moving average is $47.27. The company has a debt-to-equity ratio of 4.30, a quick ratio of 2.91 and a current ratio of 4.44.

Establishment Labs (NASDAQ:ESTA) last issued its earnings results on Tuesday, August 6th. The company reported ($0.62) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.11). The business had revenue of $44.12 million during the quarter, compared to the consensus estimate of $43.10 million. Establishment Labs had a negative return on equity of 220.67% and a negative net margin of 54.97%. The business’s revenue was down 9.2% on a year-over-year basis. During the same period in the prior year, the business earned ($0.65) EPS. Equities analysts anticipate that Establishment Labs will post -2.2 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, CEO Quiros Juan Jose Chacon sold 3,641 shares of Establishment Labs stock in a transaction that occurred on Thursday, July 11th. The stock was sold at an average price of $45.04, for a total value of $163,990.64. Following the sale, the chief executive officer now owns 210,735 shares of the company’s stock, valued at approximately $9,491,504.40. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Corporate insiders own 11.44% of the company’s stock.

Institutional Investors Weigh In On Establishment Labs

Institutional investors have recently made changes to their positions in the company. Hood River Capital Management LLC acquired a new position in Establishment Labs in the 2nd quarter valued at $43,000. Nkcfo LLC acquired a new position in shares of Establishment Labs in the 2nd quarter valued at about $227,000. Concurrent Investment Advisors LLC acquired a new stake in shares of Establishment Labs during the 1st quarter worth approximately $263,000. SG Americas Securities LLC bought a new stake in Establishment Labs in the second quarter valued at $303,000. Finally, Bay Colony Advisory Group Inc d b a Bay Colony Advisors bought a new position in Establishment Labs in the second quarter worth approximately $373,000. Institutional investors own 72.91% of the company’s stock.

About Establishment Labs

Establishment Labs Holdings Inc, a medical technology company, manufactures and markets medical devices for aesthetic and reconstructive plastic surgery. The company primarily offers silicone gel-filled breast implants under the Motiva Implants brand. It also provides Motiva Ergonomix and Motiva Ergonomix2 gravity sensitive round soft silicone-gel-filled breast implants; and Motiva Flora Tissue Expander, a breast tissue expander.